Merops Switch to
Peptidases

Inhibitor

Family Clan Small-molecule
inhibitor SEARCHES BLAST
MEROPS

Other
information

Literature for gemigliptin (S09.003 inhibitor)

Summary Literature Inhibits

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

    2017
  1. Gutch,M., Joshi,A., Kumar,S., Agarwal,A., Pahan,R.K. and Razi,S.M.
    Gemigliptin: newer promising gliptin for type 2 diabetes mellitus
    Indian J Endocrinol Metab (2017) 21, 898-902. PubMed  Europe PubMed DOI  PMC  EPMC  I
  2. Kim,S.H., Kang,J.G., Kim,C.S., Ihm,S.H., Choi,M.G., Yoo,H.J. and Lee,S.J.
    The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells
    Tumour Biol (2017) 39, 1010428317722068-1010428317722068. PubMed  Europe PubMed DOI  I
    3. 2016
  3. Jung,G.S., Jeon,J.H., Choe,M.S., Kim,S.W., Lee,I.K., Kim,M.K. and Park,K.G.
    Renoprotective effect of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in streptozotocin-induced type 1 diabetic mice
    Diabetes Metab J (2016) 40, 211-221. PubMed  Europe PubMed DOI  I
  4. Kim,S.H., Jung,E., Yoon,M.K., Kwon,O.H., Hwang,D.M., Kim,D.W., Kim,J., Lee,S.M. and Yim,H.J.
    Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo
    Eur J Pharmacol (2016) 788, 54-64. PubMed  Europe PubMed DOI  I
  5. Moon,J.Y., Woo,J.S., Seo,J.W., Lee,A., Kim,D.J., Kim,Y.G., Kim,S.Y., Lee,K.H., Lim,S.J., Cheng,X.W., Lee,S.H. and Kim,W.
    The dose-dependent organ-specific effects of a dipeptidyl peptidase-4 inhibitor on cardiovascular complications in a model of Type 2 diabetes
    PLoS ONE (2016) 11, e0150745-e0150745. PubMed  Europe PubMed DOI  I
    6. 2015
  6. Baek,S.H., Kim,S.H., Kim,J.W., Kim,Y.J., Lee,K.W. and Na,K.Y.
    Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial
    Trials (2015) 16, 239-239. PubMed  Europe PubMed DOI  PMC  EPMC  I
  7. Choi,S.H., Park,S., Oh,C.J., Leem,J., Park,K.G. and Lee,I.K.
    Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation
    Vascul Pharmacol (2015) 73, 11-19. PubMed  Europe PubMed DOI  I
  8. Hwang,H.J., Chung,H.S., Jung,T.W., Ryu,J.Y., Hong,H.C., Seo,J.A., Kim,S.G., Kim,N.H., Choi,K.M., Choi,D.S., Baik,S.H. and Yoo,H.J.
    The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms
    Mol Cell Endocrinol (2015) 405C, 25-34. PubMed  Europe PubMed DOI  I
  9. Jung,E., Kim,J., Kim,C.S., Kim,S.H. and Cho,M.H.
    Gemigliptin, a dipeptidyl peptidase-4 inhibitor, inhibits retinal pericyte injury in db/db mice and retinal neovascularization in mice with ischemic retinopathy
    Biochim Biophys Acta (2015) 1852, 2618-2629. PubMed  Europe PubMed DOI  I
    10. 2014
  10. Hwang,H.J., Jung,T.W., Ryu,J.Y., Hong,H.C., Choi,H.Y., Seo,J.A., Kim,S.G., Kim,N.H., Choi,K.M., Choi,D.S., Baik,S.H. and Yoo,H.J.
    Dipeptidyl petidase-IV inhibitor (gemigliptin) inhibits tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 cardiomyocytes
    Mol Cell Endocrinol (2014) 392, 1-7. PubMed  Europe PubMed DOI  I
  11. Jung,E., Kim,J., Kim,S.H., Kim,S. and Cho,M.H.
    Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo
    Eur J Pharmacol (2014) 744, 98-102. PubMed  Europe PubMed DOI  I
  12. Kim,N., Patrick,L., Mair,S., Stevens,L., Ford,G., Birks,V. and Lee,S.-H.
    Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans
    Xenobiotica (2014) 44, 522-530. PubMed  Europe PubMed DOI  I
  13. Kim,Y., Kim,U., Kim,I.S., Lee,S.H., Lee,J., Kim,D.H. and Yoo,H.H.
    Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats
    Xenobiotica (2014) 44, 627-634. PubMed  Europe PubMed DOI  I
  14. Shon,J.H., Kim,N., Park,S.J., Oh,M.K., Kim,E.Y., Lee,S.H., Kim,Y.H. and Shin,J.G.
    Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444)
    Diabetes Obes Metab (2014) 16, 1028-1031. PubMed  Europe PubMed DOI  I
    15. 2013
  15. Kim,S.H., Lee,S.H. and Yim,H.J.
    Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry
    Arch Pharm Res (2013) 36, 1185-1188. PubMed  Europe PubMed DOI  I
  16. Rhee,E.J., Lee,W.Y., Min,K.W., Shivane,V.K., Sosale,A.R., Jang,H.C., Chung,C.H., Nam-Goong,I.S., Kim,J.A. and Kim,S.W.
    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
    Diabetes Obes Metab (2013) 15, 523-530. PubMed  Europe PubMed DOI  I
    17. 2012
  17. Kim,S.E., Yi,S., Shin,K.H., Kim,T.E., Kim,M.J., Kim,Y.H., Yoon,S.H., Cho,J.Y., Shin,S.G., Jang,I.J. and Yu,K.S.
    Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers
    Int J Clin Pharmacol Ther (2012) 50, 17-23. PubMed  Europe PubMed DOI  I
  18. Noh,Y.H., Lim,H.S., Jin,S.J., Kim,M.J., Kim,Y.H., Sung,H.R., Choi,H.Y. and Bae,K.S.
    Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers
    Clin Ther (2012) 34, 1182-1194. PubMed  Europe PubMed DOI  I
    19. 2010
  19. Rhee,E.J., Lee,W.Y., Yoon,K.H., Yoo,S.J., Lee,I.K., Baik,S.H., Kim,Y.K., Lee,M.K., Park,K.S., Park,J.Y., Cha,B.S., Lee,H.W., Min,K.W., Bae,H.Y., Kim,M.J., Kim,J.A., Kim,D.K. and Kim,S.W.
    A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes
    Diabetes Obes Metab (2010) 12, 1113-1119. PubMed  Europe PubMed DOI  I
    20. 2009
  20. Lim,K.S., Cho,J.Y., Kim,B.H., Kim,J.R., Kim,H.S., Kim,D.K., Kim,S.H., Yim,H.J., Lee,S.H., Shin,S.G., Jang,I.J. and Yu,K.S.
    Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
    Br J Clin Pharmacol (2009) 68, 883-890. PubMed  Europe PubMed DOI  I
    21. 2008
  21. Lim,K.S., Kim,J.R., Choi,Y.J., Shin,K.H., Kim,K.P., Hong,J.H., Cho,J.Y., Shin,H.S., Yu,K.S., Shin,S.G., Kwon,O.H., Hwang,D.M., Kim,J.A. and Jang,I.J.
    Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study
    Clin Ther (2008) 30, 1817-1830. PubMed  Europe PubMed DOI  I

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2026 EBI
Terms of use